PureTech Health (LON:PRTC) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

PureTech Health plc (LON:PRTC) shares crossed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of GBX 123.34 and traded as low as GBX 121.60. PureTech Health shares last traded at GBX 122.20, with a volume of 1,849,151 shares traded.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt restated a “buy” rating and set a GBX 508 price target on shares of PureTech Health in a report on Monday, July 13th. One research analyst has rated the stock with a Buy rating. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of GBX 508.

PureTech Health Stock Performance

The firm’s 50 day simple moving average is GBX 117.12 and its 200-day simple moving average is GBX 123.34. The company has a market capitalization of £289.31 million, a price-to-earnings ratio of -2.34 and a beta of 0.77. The company has a debt-to-equity ratio of 4.78, a quick ratio of 2.51 and a current ratio of 4.60.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.